U.S. markets open in 1 hour 7 minutes
  • S&P Futures

    3,333.50
    -49.50 (-1.46%)
     
  • Dow Futures

    26,889.00
    -476.00 (-1.74%)
     
  • Nasdaq Futures

    11,441.00
    -147.00 (-1.27%)
     
  • Russell 2000 Futures

    1,558.90
    -30.10 (-1.89%)
     
  • Crude Oil

    37.71
    -1.86 (-4.70%)
     
  • Gold

    1,888.60
    -23.30 (-1.22%)
     
  • Silver

    23.93
    -0.64 (-2.58%)
     
  • EUR/USD

    1.1733
    -0.0057 (-0.48%)
     
  • 10-Yr Bond

    0.7780
    0.0000 (0.00%)
     
  • Vix

    36.86
    +4.40 (+13.56%)
     
  • GBP/USD

    1.2950
    -0.0091 (-0.70%)
     
  • USD/JPY

    104.3300
    -0.1640 (-0.16%)
     
  • BTC-USD

    13,302.52
    -407.50 (-2.97%)
     
  • CMC Crypto 200

    262.83
    +1.54 (+0.59%)
     
  • FTSE 100

    5,626.43
    -102.56 (-1.79%)
     
  • Nikkei 225

    23,418.51
    -67.29 (-0.29%)
     

Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019

HOUSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, August 15, 2019 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2019 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 3792557. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers and is in the process of filing an IND for a Phase 1 clinical trial for solid tumors. The Company is also developing BP1002, which targets the Bcl-2 protein and is expected to be evaluated for the treatment of lymphoma and solid tumors. In addition, BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, is expected to enter Phase 1 studies in 2020.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369